Novel slow-release breast perfusion agent for preventing cow subclinical mastitis in milk shortage stage

A technology of recessive mastitis and perfusion agent, which is applied in sexual diseases, aerosol delivery, emulsion delivery, etc., can solve the problems of changes in milk composition, blind teats, and increase in the number of milk somatic cells, and achieves good stability, The effect of reducing the frequency of administration and preventing recessive mastitis in dairy cows

Active Publication Date: 2013-08-07
中国牧工商集团有限公司 +1
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Recessive mastitis in dairy cows has no obvious clinical symptoms. It is manifested as an increase in the somatic cell count of milk, a decrease in milk production, and changes in the composition of milk, thereby affecting the quality of milk
If it is not treated in time or improperly treated, it will develop into clinical mastitis, and even cause blind teats. In severe cases, cows will be eliminated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel slow-release breast perfusion agent for preventing cow subclinical mastitis in milk shortage stage
  • Novel slow-release breast perfusion agent for preventing cow subclinical mastitis in milk shortage stage
  • Novel slow-release breast perfusion agent for preventing cow subclinical mastitis in milk shortage stage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1 Sustained-release udder perfusion agent for preventing latent mastitis in cows during the dry period and its preparation

[0017] The composition of each 100g perfusion agent is as follows:

[0018]

[0019] Grind the cefaroline raw material until more than 90% of the particle diameter reaches 3-5 μm, and sterilize it to meet the aseptic requirements, which is material A; sterilize the liquid paraffin (sterilized by filtering with a sterile filter membrane), and add polyethylene glycol -400 (PEG-400), fatty alcohol polyoxyethylene ether (AEO-7) and aluminum stearate, stir and mix, continue to heat for 5 hours, cool down to room temperature, and become liquid B; mix material A, liquid B, vitamin E. Benzyl alcohol is fed into a high-pressure homogenizer, and the high-pressure homogenizer is used to circulate and homogenize for 7 minutes. The pressure is controlled at 50MPa, and the quantification is 100g. Packing, sealing, and packaging.

Embodiment 2

[0020] Example 2 Sustained-release udder perfusion agent for preventing latent mastitis in cows during the dry period and its preparation

[0021] The composition of each 100g perfusion agent is as follows:

[0022]

[0023] Grind the cefuroxime raw material until more than 95% of the particle diameter reaches 3-5 μm, and sterilize to meet the aseptic requirements, which is material A; sterilize the liquid paraffin (sterilize by filtering with a sterile filter membrane), and add polyethylene glycol -400 (PEG-400), fatty alcohol polyoxyethylene ether (AEO-7) and aluminum stearate, stir and mix, continue to heat for 4 hours, cool down to room temperature, and become liquid B; material A, liquid B, vitamin E. Benzyl alcohol is fed into a high-pressure homogenizer, and the high-pressure homogenizer is used to circulate and homogenize for 5 minutes. The pressure is controlled at 150MPa, and the quantification is 100g. Packing, sealing, and packaging.

Embodiment 3

[0024] Example 3 Sustained-release udder perfusion agent for preventing latent mastitis in cows during the dry period and its preparation

[0025] The composition of each 100g perfusion agent is as follows:

[0026]

[0027] Grind the raw material of ceftaroline until more than 90% of the particles reach a diameter of 3-5 μm, and sterilize to meet the requirements of sterility, which is material A; sterilize the soybean oil for injection (sterilize by filtering with a sterile filter membrane), and add Tween -80, cyclomethylene glyceryl ether and aluminum stearate, stir and mix, continue to heat for 5 hours, cool down to room temperature, and become liquid B; feed material A, liquid B, vitamin E, and benzyl alcohol into a high-pressure homogenizer , use a high-pressure homogenizer to circulate and homogenize for 9 minutes, control the pressure at 120MPa, quantify to 100g, sub-package, seal and pack.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention provides a novel slow-release breast perfusion agent for preventing cow subclinical mastitis in a milk shortage stage. 100g of the novel slow-release breast perfusion agent comprises 7-11g of cefalonium, 0.5 to 8g of polyethylene glycol-400, Tween materials or propylene glycol, 0.5 to 8g of fatty alcohol polyoxyethylene ether, cyclomethylene glyceryl ether, triacetin or poloxamer, 0.5 to 8g of aluminum stearate or silica, 0.02 to 0.05g of vitamin E, 0.05 to 0.1g of benzyl alcohol, and the balance liquid paraffin, soybean oil for injection or median chain triglyceride. The invention also provides a preparation method of the novel slow-release breast perfusion agent. The novel slow-release breast perfusion agent is suspension colloid, can be slowly released, can effectively reduce administration frequency, can effectively prevent and treat cow subclinical mastitis by being used in a milk shortage stage, and does not produce residues. Compared with the like foreign products, the suspension colloid has better stability.

Description

technical field [0001] The invention relates to the field of veterinary drug preparation, in particular to a slow-release udder perfusion agent for preventing latent mastitis in cows and a preparation method thereof. Background technique [0002] Dairy cow mastitis is one of the common diseases that endanger the dairy farming industry. About 50% of the world's dairy cows suffer from various types of dairy cow mastitis, causing huge economic losses to the dairy farming industry. The main cause of mastitis in dairy cows is pathogenic microbial infection, among which five pathogenic types, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus uberis and various Gram-negative bacteria, are the most common. Recessive mastitis in dairy cows has no obvious clinical symptoms. It is manifested as an increase in somatic cell count in milk, a decrease in milk production, and changes in the composition of milk, thereby affecting the quality of milk. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/10A61K31/546A61K9/06A61P15/14
Inventor 吴家鑫葛辛玫宋敏何继红张刚张传良张淼巴利民齐鹏郑应华赵梅仙
Owner 中国牧工商集团有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap